Specialized Pro-Resolving Mediators (SPMs) Shown to Resolve Inflammation and Improve Infection Clearance Fort Lauderdale, FL, Jan. 13, 2021 (GLOBE NEWSWIRE) -- A recent review article describes how compounds called specialized pro-resolving mediators (SPMs) may be a viable treatment for inflammatory...

Corbus Pharmaceuticals Announces Presentation of Six Abstracts at EULAR 2019 Annual Meeting New data from ongoing Phase 2 open-label extension of lenabasum in systemic sclerosis and open-label extension data in dermatomyositis studies to be presentedPresentation includes data from some...

Corbus Pharmaceuticals Announces Issuance of Composition of Matter Patent Related to Lenabasum Company’s vision is to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemLenabasum in late-stage clinical studies in three orphan...